Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Human endogenous retrovirus K102 (HERV-K102) is a replication
competent protector foamy retrovirus located on chromosome 1
and is unique to humans. It appears to be a crucial component of
the innate anti-viral response launched in macrophages in response
to viruses which renders the activated macrophages foamy (FM).
Various lines of evidence suggest the HERV-K102 innate defense
system may be critical to host survival against emerging RNA
viruses. However, the release of HERV-K102 particles from FM
can be impeded by age or stress called immunosenescence (IMS).
IMS is a well-established clinical risk factor for COVID-19 severity.
It has been suggested IMS involves the reduced inactivation of
alpha-fetoprotein (AFP) by declining levels of DHEA associated
with age and/or stress. Newer evidence suggests SARS-CoV-2
may specifically target the innate anti-viral response and uniquely
disrupts foam cell formation by blocking the mevalonate pathway,
in addition to the deregulation of IL-6. The molecular pathways
common to IMS and COVID-19 pathogenesis appear to converge
on the glucocorticoid receptor (stress) regulatory network and
the IL6ST (trans-signalling IL-6 receptor) inflammatory pathway
both which involve active AFP and IL-6. On the other hand, CCR5
receptor blockade has shown promise clinically against COVID-19.
Of relevance, AFP is known to interact with CCR5, to inhibit the
pro-apoptotic effects of CASP3 while TGFB-1 is known to bind
and activate AFP. In this regard, newer evidence by N Li et al
(2020) suggests the antiviral ivermectin targets these SARSCoV-
2 interacting proteins. Moreover, ivermectin appears to have
remarkable efficacy and effectiveness for the prevention and
treatment of COVID-19. In conclusion, ivermectin may provide
significant protection against emerging RNA viruses potentially
by circumventing the adverse effects of active AFP in IMS and
COVID-19 pathogenesis, allowing for the launch of the HERV-K102
innate protector system in FM.
Relevant References
Laderoute MP. The HERV-K102 innate immunity host defense system
against emerging RNA viruses potentially enhanced in COVID-19
by ivermectin. (manuscript in preparation).
Laderoute MP. The paradigm of immunosenescence in
atherosclerosis-cardiovascular disease (ASCVD). Discovery
Medicine 2020, 29 (156): 41-51
Laderoute M. Clues to finding correlates of risk/protection for
HIV-1 vaccines F1000 Research 2018, 6:868 (doi: 10.12688/
f1000research.11818.2). https://f1000research.com/
articles/6-868
Laderoute MP. A new paradigm about HERV-K102 particle
production and blocked release to explain cortisol mediated
immunosenescence and age-associated risk of chronic disease.
Discovery Medicine 2015, 20 (112): 379-391
Laderoute MP, Larocque LJ, Giulivi A, Diaz-Mitoma F. Further
evidence that human endogenous retrovirus K102 is a replication
competent foamy virus that may antagonize HIV-1 replication.
Open AIDS J. 9:112-22 (2015)
Laderoute MP, Giulivi A, Larocque L, Bellfoy D, Hou Y, Wu HX,
Fowke K, Wu J, Diaz-Mitoma F. The replicative activity of human
endogenous retrovirus K102 (HERV-K102) with HIV viremia. AIDS.
2007 Nov 30;21(18):2417-24
Biography
Laderoute is currently a voluntary consultant for ISM-Immune System Management in Ottawa. She was the Lab Director from 2011 to 2020 where she was inspired to publish the new immunosenescence paradigm. Prior to this she was Research Manager of the Blood Zoonotics Unit at the Public Health Agency of Canada when she discovered HERV-K102 as a protector foamy virus of humans (internationally patented but now abandoned). She obtained her Ph.D. in Medical Sciences-Immunology at the University of Alberta in 1991. She published a unified theory of cancer in 1994 based on her Ph.D. discovery of the 67 Kd AFP receptor/binding proteins in tumors and macrophages, which attempted to explain how the malignant phenotype of tumors related to immunosuppression of the host via active AFP. While this was considered heretical at the time, new evidence with CCR5 blockers and knowledge of reversible EMT now suggests she may have been correct.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, 黑料网 Journals